Early Phase 1 Sickle Cell Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who have a confirmed diagnosis of sickle cell disease (any type), thalassemia (alpha or beta), or another inherited blood disorder affecting haemoglobin
- People whose blood disorder is currently stable, or who have previously had a bone marrow transplant, as shown in their medical history
- People who are willing and able to have blood samples taken
- People who are willing to follow all study procedures for the full duration of the trial
- People who are able to sign and date a consent form agreeing to take part
- Women who could become pregnant must agree to use an approved form of contraception (such as the pill, an IUD, a barrier method with spermicide, or a contraceptive implant or injection) from the start of screening until at least 4 months after the infusion
- People who agree to follow any lifestyle guidelines set out by the study for its duration
Who may not be able to join:
- People who have consumed biotin supplements or raw eggs in the last 30 days
- People who have lost more than 540 mL of blood in the past 8 weeks
- People who have received a red blood cell transfusion for their sickle cell disease or thalassemia in the last 3 months (the trial site may consider eligibility again after 3 months have passed since the last transfusion)
- People who are currently on haemodialysis (kidney dialysis)
- People who are pregnant or breastfeeding, or fertile women who are not using adequate contraception
- People under the age of 18
- People with a known allergy to biotin, due to the risk of a serious allergic reaction
- People currently diagnosed with any form of cancer (blood cancer or solid tumour)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John F Tisdale, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Phone: (301) 529-7863
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine and compare red blood cell survival, by virtue of the mean number of days of detectable biotin-labeled RBCs, in participants with SCD and/or other hemoglobinopathies.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.